For the year ending 2025-12-31, CTMX made $76,201K in revenue. -$20,370K in net income. Net profit margin of -26.73%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 76,201 | 138,103 | ||
| Research and development | 68,728 | 83,382 | ||
| General and administrative | 29,837 | 29,726 | ||
| Total operating expenses | 98,565 | 113,108 | ||
| Income (loss) from operations | -22,364 | 24,995 | ||
| Interest income | 5,206 | 7,136 | ||
| Other income (expense), net | 28 | -38 | ||
| Income (loss) before income taxes | -17,130 | 32,093 | ||
| Provision for income taxes | 238 | 224 | ||
| Net income (loss) | -17,368 | 31,869 | ||
| Unrealized gain (loss) on available-for-sale investments, net of tax | - | -68 | ||
| Deemed dividend on warrants | -3,002 | - | ||
| Total comprehensive income (loss) | - | 31,801 | ||
| Net income (loss) attributable to common stockholders | -20,370 | - | ||
| Basic Average Shares | 137,935,873 | 84,439,303 | ||
| Diluted Average Shares | 137,935,873 | 84,745,116 | ||
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)